Patents by Inventor Fabien Schmidlin

Fabien Schmidlin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMBINATION OF TASQUINIMOD OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND A PD-1 AND/OR PD-L1 INHIBITOR, FOR USE AS A MEDICAMENT
    Publication number: 20240122915
    Abstract: The present invention concerns a combination comprising tasquinimod, or a pharmaceutically acceptable salt thereof, and a PD-1 and/or PD-L1 inhibitor, for use as a medicament. It also concerns a pharmaceutical composition comprising tasquinimod, or a pharmaceutically acceptable salt thereof, and PD-1 and/or PD-L1 inhibitor.
    Type: Application
    Filed: May 11, 2023
    Publication date: April 18, 2024
    Applicant: ACTIVE BIOTECH AB
    Inventors: Jose Amauri SOARES, Eric CHETAILLE, Jessica NAKHLE, Fabien SCHMIDLIN
  • TASQUINIMOD OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF FOR USE IN COMBINATION THERAPY
    Publication number: 20230085883
    Abstract: A combination comprising tasquinimod, or a pharmaceutically acceptable salt thereof, and at least one further compound selected from a proteasome inhibitor, an immunomodulatory imide, and an antibody, for use as a in the treatment of multiple myeloma. A kit comprising tasquinimod and a package insert with instructions for using tasquinimod in combination with at least one further compound selected from a proteasome inhibitor, an immunomodulatory imide, and an antibody, to treat multiple myeloma in an individual. Tasquinimod for use in the treatment of multiple myeloma, in combination with a further compound selected from a proteasome inhibitor, an immunomodulatory imide, and an antibody.
    Type: Application
    Filed: March 3, 2021
    Publication date: March 23, 2023
    Inventors: Yuliya NEFEDOVA, Marie TÖRNGREN, Helena ERIKSSON, Dmitry GABRILOVICH, Fabien SCHMIDLIN
  • COMBINATION OF TASQUINIMOD OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND A PD-1 AND/OR PD-L1 INHIBITOR, FOR USE AS A MEDICAMENT
    Publication number: 20200129499
    Abstract: The present invention concerns a combination comprising tasquinimod, or a pharmaceutically acceptable salt thereof, and a PD-1 and/or PD-L1 inhibitor, for use as a medicament. It also concerns a pharmaceutical composition comprising tasquinimod, or a pharmaceutically acceptable salt thereof, and PD-1 and/or PD-L1 inhibitor.
    Type: Application
    Filed: December 17, 2019
    Publication date: April 30, 2020
    Applicant: ACTIVE BIOTECH AB
    Inventors: Jose Amauri SOARES, Eric CHETAILLE, Jessica NAKHLE, Fabien SCHMIDLIN
  • COMBINATION OF TASQUINIMOD OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND A PD-1 AND/OR PD-L1 INHIBITOR, FOR USE AS A MEDICAMENT
    Publication number: 20180050030
    Abstract: The present invention concerns a combination comprising tasquinimod, or a pharmaceutically acceptable salt thereof, and a PD-1 and/or PD-L1 inhibitor, for use as a medicament. It also concerns a pharmaceutical composition comprising tasquinimod, or a pharmaceutically acceptable salt thereof, and PD-1 and/or PD-L1 inhibitor.
    Type: Application
    Filed: February 16, 2016
    Publication date: February 22, 2018
    Inventors: José Amauri SOARES, Eric CHETAILLE, Jessica NAKHLE, Fabien SCHMIDLIN
  • Fused pyrrolidino-cyclopropane derivatives as selective 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors
    Patent number: 8486964
    Abstract: The present invention relates to fused pyrrolidino-cyclopropane derivatives according to formulae (I) to (IV) as selective inhibitors of the enzyme 11-beta-hydroxysteroid dehydrogenase type 1 (11-?-HSD-1) and the use of such compounds for the treatment and/or prevention of metabolic syndrome, diabetes, insulin resistance, obesity, lipid disorders, glaucoma, osteoporosis, cognitive disorders, anxiety, depression, immune disorders, hypertension and other diseases and conditions.
    Type: Grant
    Filed: August 5, 2009
    Date of Patent: July 16, 2013
    Assignee: Merck Patent GmbH
    Inventors: Eric Valeur, Franck Lepifre, Didier Roche, Denis Carniato, Serge Christmann-Franck, Fabien Schmidlin